A new kind of flu vaccine is being considered by U.S. health advisers. The vaccine, made by Moderna, uses the same mRNA technology that was key to ending the COVID-19 pandemic. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season.

How the Vaccine Works

The mRNA vaccine works by using a piece of genetic material called messenger RNA to instruct cells in the body to produce a specific protein. This protein is then recognized by the immune system, which mounts a response to fight off the flu virus. In a study of 40,000 people age 50 and older, Moderna’s mRNA vaccine reduced flu cases by about 27% compared to those given another routinely used vaccine brand.

Moderna is seeking full approval for the vaccine’s use in the 50- to 64-year-old population — along with authorization for use in those 65 and older while it conducts additional testing. The FDA’s initial review noted the new vaccine lacks data on very frail older adults and those with weak immune systems.

Original reporting: WPBF West Palm Beach — read the source article.